Say you’re a kid playing a video game on a tablet. You navigate through landscapes like a molten lava river and an icy winter wonderland, then get rewarded with stars and points when you complete tasks.

That all sounds pretty standard, but one game maker, Akili Interactive Labs of Boston, hopes its video game will become the first one approved by the Food and Drug Administration, and then prescribed for kids with ADHD. (The agency is currently reviewing the product.) Akili sees the video game as the delivery system for targeted algorithms that act as a medical device to activate certain neural networks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy